Filing Flows › Arcutis Biotherapeutics (ARQT) › Q1 2025
Arcutis Biotherapeutics (ARQT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Arcutis Biotherapeutics (ARQT) reported revenue of $65.8M for the first quarter 2025 (Q1 2025), +33% from a year earlier and -8% from the quarter before. Operating margin was -37.3%, net loss $25.1M (38.1% of revenue).
Arcutis Biotherapeutics, Q1 2025: revenue $65.8M (+33% year over year), operating margin -37.3%, net loss $25.1M, operating cash flow −$30.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $65.8M | -8% | +33% |
| Operating profit | −$24.5M | — | — |
| Net earnings | −$25.1M | — | — |
| Operating cash flow | −$30.4M | — | — |
What changed
Revenue was $65.8M in Q1 2025, up 33% year over year and down 8% from the previous quarter. ZORYVE foam was the largest line at 46% of revenue. ZORYVE foam added $23.7M year over year (up 362%), 146% of the total change.
Operating costs exceeded revenue by $24.5M, an operating margin of -37.3%. Total costs grew 11% against revenue growth of 33%. The fastest-growing cost line was Cost of revenue (+171%). The quarter ended with a net loss of $25.1M, wider than the previous quarter's $10.8M loss.
Operating cash flow was −$30.4M. Non-cash charges added back $3.1M of depreciation and amortization and $9.8M of share-based compensation. Working capital and other items used $18.2M. Capital expenditures of $608K exceeded it, leaving free cash flow of −$31.0M.
Questions
What was Arcutis Biotherapeutics' revenue in the first quarter 2025?
Arcutis Biotherapeutics (ARQT) reported revenue of $65.8M for the first quarter 2025 (Q1 2025), +33% from a year earlier and -8% from the quarter before.
Was Arcutis Biotherapeutics profitable in the first quarter 2025?
Operating loss was $24.5M (-37.3% of revenue) and net loss $25.1M.